Virus Image

NOTE: The Cape May County Herald is offering full coverage of the COVID-19 / coronavirus emergency to all, with no payment required. We are committed to ensuring our readers can make critical decisions for themselves and their families during this ongoing situation. To continue supporting this vital reporting, please consider a digital subscription or contribution. For more coverage, subscribe to our daily newsletter.

COURT HOUSE - July 28: Cape May County reports that eight COVID-19 cases were found today, five community based and three non-residents.

Untitled.png

According to a release, New Jersey has 180,295 total COVID-19 positive cases and 13,905 deaths. Total positive cases of COVID-19 infection in Cape May County is now 964, including 81 deaths. 

Phase 3 clinical trial of investigational vaccine for COVID-19 begins

According to the National Institutes of Health, a Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial, which will be conducted at U.S. clinical research sites, is expected to enroll approximately 30,000 adult volunteers who do not have COVID-19.

Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a Phase 3 clinical trial. This scientifically rigorous, randomized, placebo-controlled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last.

Moderna is leading the trial as the regulatory sponsor and is providing the investigational vaccine for the trial. The Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and NIAID are providing funding support for the trial. The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a multi-agency collaboration led by HHS that aims to accelerate the development, manufacturing and distribution of medical countermeasures for COVID-19.

“Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it’s the right goal for the American people,” stated National Institutes of Health Director Francis S. Collins, M.D., Ph.D. “The launch of this Phase 3 trial in record time while maintaining the most stringent safety measures demonstrates American ingenuity at its best and what can be done when stakeholders come together with unassailable objectivity toward a common goal.” 

Untitled (1).png

Introducing 'The Wrap', a new way to get the news.

We wrap up the news from the Shore you love, and deliver it to your inbox, weekly.

Load comments